Rifampin

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococci, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc.

Chemical name: 3-[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin Molecular weight: C43H58N4O12

This product is a sugar-coated tablet. After removing the coating, it appears orange-red or dark red.

This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment treatment of various tuberculosis, including the treatment of tuberculous meningitis.

1. Anti-tuberculosis treatment: Adults, oral, 0.45g ~ 0.60g a day, fasting, no more than 1.2g a day; children over 1 month old, 10 ~ 20mg/kg a day, fasting, no more than 0.6g a day. 2. Meningococcal Neisseria carriers: Adults 5mg/kg, once every 12 hours, for 2 consecutive days; children over 1 month old, 10mg/kg a day, once every 12 hours, for 4 consecutive times. 3. Elderly patients, oral, 10mg/kg a day, fasting.

1. Digestive tract reactions are the most common. Gastrointestinal reactions such as anorexia, nausea, vomiting, upper abdominal discomfort, diarrhea, etc. may occur after oral administration of the product, with an incidence of 1.7% to 4.0%, but they are all tolerable. 2. Hepatotoxicity is the main adverse reaction of this product, with an incidence of about 1%. In the first few weeks of treatment, a small number of patients may experience elevated serum aminotransferase, hepatomegaly, and jaundice. Most of them are asymptomatic transient elevations of serum aminotransferases, which can recover on their own during the course of treatment. The elderly, alcoholics, malnourished people, those with pre-existing liver disease or other factors causing abnormal liver function are more likely to develop the disease. 3. Allergic reactions: Flu-like syndrome may occasionally occur after high-dose intermittent therapy, manifested by chills, chills, fever, malaise, dyspnea, dizziness, drowsiness, and muscle pain.

1. Patients who are allergic to this product or rifamycin antibiotics are contraindicated. 2. Patients with severe liver dysfunction, biliary obstruction and pregnant women within 3 months are contraindicated.

Precautions for children: The safety of this product for children under 5 years old has not been established. Precautions for pregnancy and lactation: Please follow the doctor's advice. Precautions for the elderly: Elderly patients have decreased liver function and the dosage should be reduced as appropriate.

1. Drinking alcohol can increase the incidence of rifampicin hepatotoxicity and increase the metabolism of rifampicin. The rifampicin dose needs to be adjusted, and the patient should be closely observed for liver toxicity. 2. Para-aminosalicylate can affect the absorption of this product, resulting in a decrease in its blood concentration; if combined use is necessary, the two should be taken at least 6 hours apart. 3. The risk of hepatotoxicity increases when this product is used in combination with isoniazid, especially in patients with pre-existing liver damage and patients with rapid acetylation of isoniazid. 4. The combined use of rifampicin and ethionamide can aggravate its adverse reactions. 5. Chlorphenazine can reduce the absorption of rifampicin, delay the peak time and prolong the half-life. 6. The combination of rifampicin with miconazole or ketoconazole can reduce the blood concentrations of the latter two, so this product should not be used in combination with imidazoles.

Keep in a light-proof and airtight container.

36 months

Chengdu Jinhua Pharmaceutical Co., Ltd.

• Founded in:

  1990-06-09

• Address:

  No. 281, Section 4, Xihanggang Avenue, Shuangliu District, Chengdu

• Tax NO.:

  91510122202381139Y

• Registered Funds:

  20.79918 million yuan

• Website:

  Log in to view

• Email:

  Log in to view